This study utilizes a combination of sequence data analysis, molecular docking, virtual screening, and molecular dynamics simulation to detect drug resistance mutations in NSCLC patients and identify three compounds that show promise to inhibit EGFR mutant proteins. This evidence concerns the gene EGFR and non-small cell lung carcinoma.